Introduction
early graft loss [4] . In a large multicentre study including 142 patients, the 1-year allograft survival rate after Renal transplantation among patients with end-stage cadaveric transplantation of patients with SLE was renal disease ( ESRD) caused by lupus nephritis has 67%, significantly worse than that of patients without become an accepted alternative for long-term treat-SLE [5] . After one year, most studies showed that ment. However, the outcome of renal transplantation graft survival in lupus patients was similar to that in in patients with systemic lupus erythematosus (SLE) control population [2] . These conflicting data may be is still controversial. Infection, recurrent disease, both secondary to differences in donor source, type of acute and chronic rejection, and thrombosis may play immunosuppression, and composition of the control a role in early graft loss. New findings for graft and group. It is also important to analyse separately the patient outcome, immunological markers and immunoresults for patients who received cadaveric vs livingsuppressive treatment have recently emerged. We discuss these different aspects here, with the exception related transplants. A recent study conducted within of the clinical consequences of the presence of the United States Renal Data system, in which comparanti-endothelial cell antibodies.
isons were adjusted for possible confounding factors, showed that graft survival and patient survival after a first renal transplantation were similar for patients
Outcome analysis
with ESRD caused by lupus nephritis and patients with ESRD from other causes [6 ] . Reported patient An initial report that early graft survival in SLE survival at 1, 3 and 5 years was 94.4, 89.6 and 83.8% patients was comparable to that of patients with other respectively. Graft survival for same time periods was causes of ESRD has been confirmed by subsequent 79.1, 67.0 and 58.1% respectively. In this study, patients studies [1, 2] . However, several of these studies were with ESRD due to lupus nephritis were younger, more conducted in single centres with small numbers of likely to be women, and more likely to be Black or patients. Furthermore, in these studies the control Asian, than patients with other causes of underlying group was often historical. In larger multicentre studies renal disease. The SLE patients had also received more and reports based on registry data, cadaveric graft blood transfusions. It is important to take into account survival often tended to be lower when ESRD was these confounding factors, because statistical analysis caused by lupus nephritis than when SLE was not demonstrated a higher risk of graft loss in an unadinvolved. In these studies, the reported incidence of justed model, but no difference in an adjusted model. early graft loss in SLE patients varied between 25 and Thus in our opinion this study demonstrates that lupus 40% during the first month after transplantation [3] . nephritis per se is not a greater risk factor for poor In a meta-analysis of several series of renal transplant outcome after renal transplantation than other causes recipients, including 770 patients with SLE, the authors of ESRD. Unfortunately, reliable data are not avail- with the outcome of those treated by dialysis.
screening on the day of transplantation is important
Specific risk factors for patients with lupus
for prospective evaluation after transplantation.
nephritis

Thrombotic complications Immunological failure
Thrombotic complications play an important role in The increased incidence of immunological failure and early graft losses in lupus patients, especially when its role in graft loss is also controversial. Thus, antiphospholipid antibodies (APAs) are present. APAs although Grimbert et al. [1] found no increased risk are directed against the b2-glycoprotein I ( b2GPI ) of such failure in lupus patients, others reported a rather than the phospholipid itself. They prolong phoshigher incidence of acute rejection during the first year pholipid-dependent coagulation in vitro, but are associin SLE patients than in a control population (69 vs ated with thrombosis in vivo. APAs have been reported 56%; P=0.01). The incidence of chronic rejection may to be present in 30-44% of patients with SLE. After also be higher in SLE patients [7] . Immunological transplantation, renal-artery or -vein thrombosis has failure may be associated with increased panel reactive also been reported in lupus patients, and according to antibodies in SLE patients, which may be partly due one report, renal-artery thrombosis was responsible to the presence of non-HLA lymphocytotoxic antibodfor 6% of graft losses when APAs were present. The ies. Blood transfusions are also more frequently needed role of APAs was stressed by Radhakrishnan et al. in patients with ESRD caused by lupus nephritis.
[10]. In SLE patients, these authors reported four thrombotic events in five patients who were APA Disease activity and recurrent nephritis positive, vs none in five APA-negative patients. However, these events were not associated with graft Usually, disease activity declines after renal transloss or death. In the absence of a controlled prospective plantation. In a Dutch analysis, most patients (72%) trial, patients with APA and a history of recurrent had no disease activity after renal transplantation, as thrombosis who undergo transplantation should be judged by systemic lupus erythematosus disease activity treated with effective anticoagulation, both during and index scores, even though there have been individual after transplantation. reports of patients developing recurrent SLE activity after transplantation [8] . Serological parameters appear to be unreliable markers of both recurrence
Immunosuppressive treatment
and outcome after transplantation. A brief period of dialysis treatment before transplantation (i.e. less than To date, no study has dealt either with the effects of 6 months) had no adverse effect on transplantation new immunosuppressive drugs on short-and longoutcome in most studies.
term survival, or with the incidence of recurrent nephRecurrence of lupus nephritis in transplanted kidney ritis. Among new treatments, mycophenolate mofetil is unusual, and its reported incidence is 1-3%.
(MMF ) and co-stimulation inhibitors are promising. However, this incidence may have been underesti-MMF is an inhibitor of purine synthesis. It was found mated, because of the absence of routine biopsies, and to be effective in the prevention of progressive nephritis of the similarities between recurrent lesions and other in a murine model of SLE [11] . In humans, both lesions observed during the course of renal transplantaencouraging results and less successful uncontrolled tion. Nyberg et al. [9] reported a recurrence rate of experience have been reported. A controlled trial is 43% among 16 SLE patients. The choice of the paraurgently needed. The effects of antibodies against the meters used by them to define recurrence, namely co-stimulatory molecules CD154 and B7 have also mesangial proliferation and deposition of IgM and C3, been evaluated in animal models of renal transplantamay explain this high incidence because these paration and lupus nephritis, and these antibodies will meters lack specificity. The clinical consequences of probably be used in the future. recurrent nephritis may be serious. In one study, it was the cause of graft loss in four of nine patients with recurrent nephritis. The recent report of the complete Conclusion disappearance of histological lesions in two renal allografts with initial lesions of class IV/V lupus nephritis demonstrated partial effectiveness of the currently used Renal transplantation is a good alternative for treatment of SLE patients with ESRD. However, data immunosuppressive treatments. Finally, although the same results for both graft survival and lupus recur-permitting comparison of the effects of renal transplantation and dialysis are lacking. Lupus patients rence have been reported after cadaveric and livingdonor transplantation, even from a monozygotic twin, carry a higher risk of immunological failure and thrombotic events. Treatment with new powerful immunoscreening for potential donors must concentrate on the search for sub-clinical or potential SLE cases. The use suppressive drugs may improve the outcome of these patients. Because many patients have received immunoof new immunosuppressive drugs that may reduce lupus activity may decrease the risk of disease recur-suppressive drugs before transplantation, special attention must be paid to the choice of anti-infectious rence. We think that transplantation may be performed even if biological disease activity is present. Complete strategy. In the long term, neoplastic complications
